Patents by Inventor Brian James Leppert

Brian James Leppert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotides for treating expanded repeat diseases
    Patent number: 11674139
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: June 13, 2023
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • Induced exon inclusion in spinal muscle atrophy
    Patent number: 10577605
    Abstract: The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 3, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Linsley, Brian James Leppert
  • OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES
    Publication number: 20190100755
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Application
    Filed: July 18, 2018
    Publication date: April 4, 2019
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
    Publication number: 20180273954
    Abstract: The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.
    Type: Application
    Filed: March 14, 2018
    Publication date: September 27, 2018
    Inventors: Peter Linsley, Brian James Leppert
  • Oligonucleotides for treating expanded repeat diseases
    Patent number: 10066228
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 4, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • Induced exon inclusion in spinal muscle atrophy
    Patent number: 9944926
    Abstract: The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 17, 2018
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Linsley, Brian James Leppert
  • INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
    Publication number: 20140329772
    Abstract: The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 6, 2014
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter Linsley, Brian James Leppert
  • OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES
    Publication number: 20140303238
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 9, 2014
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson